Acne scar Acne scar
Conditions
Interventions
Prior to each treatment, a topical anesthetic cream will be applied to the treatment area for 45 minutes. Each participant will receive two to three passes of the 2910-nm erbium-doped fluoride glass f
Experimental Device
2910 nm, erbium-doped, fluoride glass, fiber laser
Sponsors
Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand
Eligibility
Sex/Gender
All
Age
20 Years to 50 Years
Inclusion criteria
Inclusion criteria: 1. Participants of either sex aged 20 to 50 years. 2. Participants with moderate or greater facial atrophic acne scars, as assessed using the Qualitative Global Scarring Grading System 3. Participants who voluntarily consent to participate in the study.
Exclusion criteria
Exclusion criteria: 1. Pregnant or breastfeeding participants. In cases of uncertainty, a urine pregnancy test will be performed; participants with a positive test result will be excluded. 2. Participants with a history of collagen related disorders. 3. Participants with dermatitis, wounds, active skin infections, or skin cancer in the treatment area. 4. Participants who have undergone laser treatment for acne scars on the face within 6 months prior to study enrollment. 5. Participants who have received dermal filler, botulinum toxin, collagen biostimulator, platelet-rich plasma (PRP), or thread lifting treatments on the face within 6 months prior to enrollment. 6. Participants who have undergone chemical peeling or TCA CROSS within 3 months before study enrollment. 7. Participants who have used vitamin A or its derivatives within 3 months prior to enrollment. 8. Participants who have used oral or topical whitening agents within 3 months prior to the study. 9. Participants who have taken isotretinoin within 6 months prior to study enrollment. 10. Participants with a history of platelet disorders, coagulation abnormalities, or who are currently taking antiplatelet or anticoagulant medications, as well as those with conditions deemed unsafe for participation 11. Participants with a history of photosensitivity. 12. Participants with a history of hypertrophic scars or keloids in the treatment area. 13. Participants who smoke or have a history of heavy alcohol consumption. 14. Participants with a history of psychiatric disorders. 15. Participants with an alcohol allergy. 16. Participants with any medical condition that, in the investigators judgment, may pose a safety risk during participation. 17. Participants who do not consent to photography for treatment evaluation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severity of acne scar baseline, one month after the first treatment, one month after the second treatment, and at 1, 3, and 6 months after the final (third) treatment. Goodman and Baron's Quantitative Global Acne Scarring Grading System,Physician assessments one month after the first treatment, one month after the second treatment, and at 1, 3, and 6 months after the final (third) treatment. Quartile scale,Safety one month after the first treatment, one month after the second treatment, and at 1, 3, and 6 months after the final (third) treatment. adverse events | — |
Secondary
| Measure | Time frame |
|---|---|
| acne scar volume baseline, one month after the first treatment, one month after the second treatment, and at 1, 3, and 6 months after the final (third) treatment. antera3D,skin texture baseline, one month after the first treatment, one month after the second treatment, and at 1, 3, and 6 months after the final (third) treatment. Antera3D,Melanin index baseline, one month after the first treatment, one month after the second treatment, and at 1, 3, and 6 months after the final (third) treatment. Mexameter,Erythema index baseline, one month after the first treatment, one month after the second treatment, and at 1, 3, and 6 months after the final (third) treatment. Mexameter,Redness baseline, one month after the first treatment, one month after the second treatment, and at 1, 3, and 6 months after the final (third) treatment. Antera3D,Pigmentation level baseline, one month after the first treatment, one month after the second treatment, and at 1, 3, and 6 months after the final (third) treatment. Antera3D,Brown spot baseline, one month after the first treatment, one month after the second treatment, and at 1, 3, and 6 months after the final (third) treatment. VISIA,Red area baseline, one month after the first treatment, one month after the second treatment, and at 1, 3, and 6 months after the final (third) treatment. VISIA | — |
Countries
Thailand
Contacts
Public ContactWoraphong Manuskiatti
Department of Dermatology, Faculty of medicine Siriraj hospital, Mahidol university
Outcome results
None listed